US2006009481A1PendingUtilityA1
Arylindenopyridines and related therapeutic and prophylactic methods
Individually held — no corporate assignee on recordPriority: Apr 18, 2001Filed: Aug 3, 2005Published: Jan 12, 2006
Est. expiryApr 18, 2021(expired)· nominal 20-yr term from priority
C07D 405/04C07D 401/04C07D 221/16A61P 25/28C07D 491/04C07D 401/12C07D 409/04
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention provides novel arylindenopyridines of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by reducing PDE activity in appropriate cells. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
Claims
exact text as granted — not AI-modified1 . A compound having the structure
wherein
(a) R 1 is selected from the group consisting of:
(i) —COR 5 , wherein R 5 is selected from H, optionally substituted C 1-8 straight or branched chain alkyl, optionally substituted aryl and optionally substituted arylalkyl;
wherein the substituents on the alkyl, aryl and arylalkyl group are selected from C 1-8 alkoxy, phenylacetyloxy, hydroxy, halogen, p-tosyloxy, mesyloxy, amino, cyano, carboalkoxy, or NR 20 R 21 wherein R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-8 straight or branched chain alkyl, C 3-7 cycloalkyl, benzyl, aryl, or heteroaryl or NR 20 R 21 taken together form a heterocycle or heteroaryl;
(ii) COOR 6 , wherein R 6 is selected from H, optionally substituted C 1-8 straight or branched chain alkyl, optionally substituted aryl and optionally substituted arylalkyl;
wherein the substituents on the alkyl, aryl and arylalkyl group are selected from C 1-8 alkoxy, phenylacetyloxy, hydroxy, halogen, p-tosyloxy, mesyloxy, amino, cyano, carboalkoxy, or NR 20 R 21 wherein R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-8 straight or branched chain alkyl, C 3-7 cycloalkyl, benzyl, aryl, or heteroaryl or NR 20 R 21 taken together form a heterocycle or heteroaryl;
(iii) cyano;
(iv) a lactone or lactam formed with R 4 ;
(v) —CONR 7 R 8 wherein R 7 and R 8 are independently selected from H, C 1-8 straight or branched chain alkyl, C 3-7 cycloalkyl, trifluoromethyl, hydroxy, alkoxy, acyl, alkylcarbonyl, carboxyl, arylalkyl, aryl, heteroaryl and heterocyclyl;
wherein the alkyl, cycloalkyl, alkoxy, acyl, alkylcarbonyl, carboxyl, arylalkyl, aryl, heteroaryl and heterocyclyl groups may be substituted with carboxyl, alkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, hydroxamic acid, sulfonamide, sulfonyl, hydroxy, thiol, alkoxy or arylalkyl,
or R 7 and R 8 taken together with the nitrogen to which they are attached form a heterocycle or heteroaryl group;
(b) R 2 is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl and optionally substituted C 3-7 cycloalkyl; or R 2 is
(c) R 3 is from one to four groups independently selected from the group consisting of:
(i) hydrogen, halo, C 1-8 straight or branched chain alkyl, arylalkyl, C 3-7 cycloalkyl, C 1-8 alkoxy, cyano, C 1-4 carboalkoxy, trifluoromethyl, C 1-8 alkylsulfonyl, halogen, nitro, hydroxy, trifluoromethoxy, C 1-8 carboxylate, aryl, heteroaryl, and heterocyclyl;
(ii) —NR 10 R 11 wherein R 10 and R 11 are independently selected from H, C 1-8 straight or branched chain alkyl, arylalkyl, C 3-7 cycloalkyl, carboxyalkyl, aryl, heteroaryl, and heterocyclyl or R 10 and R 11 taken together with the nitrogen form a heteroaryl or heterocyclyl group;
(iii) —NR 12 COR 13 wherein R 12 is selected from hydrogen or alkyl and R 13 is selected from hydrogen, alkyl, substituted alkyl, C 1-3 alkoxyl, carboxyalkyl, R 30 R 31 N (CH 2 ) p —, R 30 R 31 NCO(CH 2 ) p —, aryl, arylalkyl, heteroaryl and heterocyclyl or R 12 and R 13 taken together with the carbonyl form a carbonyl containing heterocyclyl group, wherein , R 30 and R 31 are independently selected from H, OH, alkyl, and alkoxy, and p is an integer from 1-6,
(d) R 4 is selected from the group consisting of (i) hydrogen, (ii) C 1-3 straight or branched chain alkyl, (iii) benzyl and (iv) —NR 13 R 14 , wherein R 13 and R 14 are independently selected from hydrogen and C 1-6 alkyl;
wherein the C 1-3 alkyl and benzyl groups are optionally substituted with one or more groups selected from C 3-7 cycloalkyl, C 1-8 alkoxy, cyano, C 1-4 carboalkoxy, trifluoromethyl, C 1-8 alkylsulfonyl, halogen, nitro, hydroxy, trifluoromethoxy, C 1-8 carboxylate, amino, NR 13 R 14 , aryl and heteroaryl; and
(e) X is selected from S and O;
with the proviso that when R 4 is isopropyl, then R 3 is not halogen, and with the proviso that one or more of R 1 , R 2 , R 3 or R 4 comprses heteroaryl or heterocycle and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.
2 . The compound of claim 1 , wherein R 1 is COOR 6 , wherein R 6 is selected from H, optionally substituted C 1-8 straight or branched chain alkyl, optionally substituted aryl and optionally substituted arylalkyl.
3 . The compound of claim 2 , wherein R 6 is selected from H, or C 1-8 straight or branched chain alkyl which may be optionally substituted with a substituent selected from CN and hydroxy.
4 . The compound of claim 1 , wherein R 2 is selected from optionally substituted aryl and optionally substituted heteroaryl.
5 . The compound of claim 4 wherein the aryl or heteroaryl groups are substituted with one to five members selected from the group consisting of halogen, alkyl, alkoxy, alkoxyphenyl, halo, triflouromethyl, trifluoro or difluoromethoxy, amino, alkylamino, hydroxy, cyano, and nitro.
6 . The compound of claim 4 wherein, R 2 is optionally substituted phenyl or napthyl or R 2 is
optionally substituted, wherein the optional substituents are from one to three members selected from the group consisting of halogen, alkyl, hydroxy, cyano, and nitro.
7 . The compound of claim 1 wherein R 3 is selected from:
(i) hydrogen, halo, C 1-8 straight or branched chain alkyl, C 1-8 alkoxy, cyano, C 1-4 carboalkoxy, trifluoromethyl, C 1-8 alkylsulfonyl, halogen, nitro, and hydroxy; (ii) —NR 10 R 11 wherein R 10 and R 11 are independently selected from H, C 1-8 straight or branched chain alkyl, arylC 1-8 alkyl, C 3 - 7 cycloalkyl, carboxyC 1-8 alkyl, aryl, heteroaryl, and heterocyclyl or R 10 and R 11 taken together with the nitrogen form a heteroaryl or heterocyclyl group; (iii) —NR 12 COR 13 wherein R 12 is selected from hydrogen or alkyl and R 13 is selected from hydrogen, alkyl, substituted alkyl, C 1-3 alkoxyl, carboxyC 1-8 alkyl, aryl, arylalkyl, R 30 R 31 N (CH 2 ) p —, R 30 R 31 NCO(CH 2 ) p —, heteroaryl and heterocyclyl or R 12 and R 13 taken together with the carbonyl form a carbonyl containing heterocyclyl group, wherein, R 30 and R 31 are independently selected from H, OH, alkyl, and alkoxy, and p is an integer from 1-6.
8 . The compound of claim 7 , wherein R 3 is selected from the group consisting of:
9 . The compound of claim 1 wherein R 4 is selected from hydrogen, and C 1-3 straight or branched chain alkyl.
10 . The compound of claim 9 , wherein R 4 is selected from methyl and amino.
11 . The compound of claim 1 wherein R 1 is COOR 6 and R 2 is selected from the group consisting of substituted phenyl, and substituted naphthyl.
12 . The compound of claim 1 wherein R 1 is COOR 6 where R 6 is alkyl, R 2 is substituted phenyl or naphthyl, and R 3 is selected from the group consisting of H, nitro, amino, NHAc, halo, hydroxy, alkoxy, or a moiety of the formulae:
and R 4 is selected from hydrogen, C 1-3 straight or branched chain alkyl and amino and X is Oxygen.
13 . A compound having the structure:
wherein
(a) R 1 is selected from the group consisting of:
(i) —COR 5 , wherein R 5 is selected from H, optionally substituted C 1-8 straight or branched chain alkyl, optionally substituted aryl and optionally substituted arylalkyl;
wherein the substituents on the alkyl, aryl and arylalkyl group are selected from C 1-8 alkoxy, phenylacetyloxy, hydroxy, halogen, p-tosyloxy, mesyloxy, amino, cyano, carboalkoxy, or NR 20 R 21 wherein R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-8 straight or branched chain alkyl, C 3-7 cycloalkyl, benzyl, aryl, or heteroaryl or NR 20 R 21 taken together form a heterocycle or heteroaryl;
(ii) COOR 6 , wherein R 6 is selected from H, optionally substituted C 1-8 straight or branched chain alkyl, optionally substituted aryl and optionally substituted arylalkyl;
wherein the substituents on the alkyl, aryl and arylalkyl group are selected from C 1-8 alkoxy, phenylacetyloxy, hydroxy, halogen, p-tosyloxy, mesyloxy, amino, cyano, carboalkoxy, or NR 20 R 21 wherein R 20 and R 21 are independently selected from the group consisting of hydrogen, C 1-8 straight or branched chain alkyl, C 3-7 cycloalkyl, benzyl, aryl, or heteroaryl or NR 20 R 21 taken together form a heterocycle or heteroaryl;
(iii) cyano;
(iv) a lactone or lactam formed with R 4 ;
(v) —CONR 7 R 8 wherein R 7 and R 8 are independently selected from H, C 1-8 straight or branched chain alkyl, C 3-7 cycloalkyl, trifluoromethyl, hydroxy, alkoxy, acyl, alkylcarbonyl, carboxyl, arylalkyl, aryl, heteroaryl and heterocyclyl;
wherein the alkyl, cycloalkyl, alkoxy, acyl, alkylcarbonyl, carboxyl, arylalkyl, aryl, heteroaryl and heterocyclyl groups may be substituted with carboxyl, alkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, hydroxamic acid, sulfonamide, sulfonyl, hydroxy, thiol, alkoxy or arylalkyl,
or R 7 and R 8 taken together with the nitrogen to which they are attached form a heterocycle or heteroaryl group;
(b) R 2 is —NR 15 R 16 wherein R 15 and R 16 are independently selected from hydrogen, optionally substituted C 1-8 straight or branched chain alkyl, arylalkyl, C 3-7 cycloalkyl, aryl, heteroaryl, and heterocyclyl or R 15 and R 16 taken together with the nitrogen form a heteroaryl or heterocyclyl group; with the proviso that when R 2 is NHR 16 , R 1 is not —COOR 6 where R 6 is ethyl;
(c) R 3 is from one to four groups independently selected from the group consisting of:
(i) hydrogen, halo, C 1-8 straight or branched chain alkyl, arylalkyl, C 3-7 cycloalkyl, C 1-8 alkoxy, cyano, C 1-4 carboalkoxy, trifluoromethyl, C 1-8 alkylsulfonyl, halogen, nitro, hydroxy, trifluoromethoxy, C 1-8 carboxylate, aryl, heteroaryl, and heterocyclyl;
(ii) —NR 10 R 11 wherein R 10 and R 11 are independently selected from H, C 1-8 straight or branched chain alkyl, arylalkyl, C 3-7 cycloalkyl, carboxyalkyl, aryl, heteroaryl, and heterocyclyl or R 10 and R 11 taken together with the nitrogen form a heteroaryl or heterocyclyl group;
(iii) —NR 12 COR 13 wherein R 12 is selected from hydrogen or alkyl and R 13 is selected from hydrogen, alkyl, substituted alkyl, C 1-3 alkoxyl, carboxyalkyl, R 30 R 31 N (CH 2 ) p —, R 30 R 31 NCO(CH 2 ) p —, aryl, arylalkyl, heteroaryl and heterocyclyl or R 12 and R 13 taken together with the carbonyl form a carbonyl containing heterocyclyl group, wherein, R 30 and R 31 are independently selected from H, OH, alkyl, and alkoxy, and p is an integer from 1-6, wherein the alkyl group may be substituted with carboxyl, alkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, hydroxamic acid, sulfonamide, sulfonyl, hydroxy, thiol, alkoxy or arylalkyl;
(d) R 4 is selected from the group consisting of (i) hydrogen, (ii) C 13 straight or branched chain alkyl, (iii) benzyl and (iv) —NR 13 R 14 , wherein R 13 and R 14 are independently selected from hydrogen and C 1-6 alkyl;
wherein the C 1-3 alkyl and benzyl groups are optionally substituted with one or more groups selected from C 3-7 cycloalkyl, C 1-8 alkoxy, cyano, C 1-4 carboalkoxy, trifluoromethyl, C 1-8 alkylsulfonyl, halogen, nitro, hydroxy, trifluoromethoxy, C 1-8 carboxylate, amino, NR 13 R 14 , aryl and heteroaryl; and
(e) X is selected from S and O;
with the proviso that one or more of R 1 , R 2 , R 3 or R 4 comprises heteroaryl or heterocycle and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.
14 . The compound of claim 13 , wherein R 1 is COOR 6 wherein R 6 is alkyl, R 2 is NR 6 R 7 , and R 3 is selected from the group consisting of
halogen, and hydrogen, and R 4 is selected from hydrogen, C 1-3 straight or branched chain alkyl and amino and X is Oxygen.
15 - 47 . (canceled)Join the waitlist — get patent alerts
Track US2006009481A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.